U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (BREYANZI) for Large B-Cell Lymphoma
The U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (Breyanzi) for Large B-Cell Lymphoma On June 24, 2022, the U.S. Food and Drug Administration (FDA) announced it has approved the use of lisocabtagene maraleucel (liso-cel, Breyanzi), a chimeric antigen receptor…